HPV Jul 6, 2022 Bio-Techne Nabs CE Mark for HPV Head and Neck Cancer Test, Completes Namocell Acquisition Apr 19, 2022 PDS Biotechnology Nets $1.2M Through NJ Economic Development Program to Advance Oncology Candidates Feb 15, 2022 Mayo Clinic Exploring PDS Biotech's PDS0101, Merck's Keytruda in HPV-Associated Oropharyngeal Cancer Feb 11, 2022 Nykode Therapeutics Completes Enrollment for HPV16-Positive Cervical Cancer Vaccine Trial Oct 6, 2021 Princess Margaret Researchers Improve HPV Detection in Blood With NGS Method Premium Mar 23, 2021 European Consortium Wins €6.9M Grant to Develop HPV16-Positive Cancer Vaccine Feb 24, 2021 Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy Feb 12, 2021 Naveris Explores New Applications for ctDNA HPV Head and Neck Cancer Test Premium Nov 18, 2020 Qiagen to Develop Companion Diagnostic for BioNTech Head, Neck Cancer Treatment Oct 27, 2020 Transgene's Vaccine for HPV16-Related Cancers Shows Anti-Tumor Activity With Bavencio Sep 20, 2020 HPV, p16 May Offer Different Prognostic Clues in Oropharyngeal Cancer, ESMO Data Reveals Premium Sep 16, 2020 FDA Approves Expanded Use for Roche Cytology Test in Patients With Cervical Cancer Aug 31, 2020 Precigen Testing Whether its Vaccine Can Raise T-Cell Army Against HPV-Positive Cancers Premium Aug 17, 2020 Precigen Doses First Patient in Phase I/II Immunotherapy Trial For HPV-Associated Cancers Jun 15, 2020 Merck Garners FDA Approval for Gardasil Vaccine for HPV-Linked Head, Neck Cancer Prevention Apr 20, 2020 Precigen to Initiate Phase I/II Trial for Novel Immunotherapy in HPV-Positive Cancers Jan 23, 2020 Viral Cancer Early Detection Efforts Making Progress Toward the Clinic Premium May 16, 2019 Qiagen, Inovio to Develop CDx for Immunotherapy Targeting Precancerous Cervical Lesions Breaking News European Commission Approves Libtayo in PD-L1-Positive Non-Small Cell Lung Cancer NICE Backs Merck's Keytruda for PD-L1-Expressing Cervical Cancer Genialis Closes $13M Series A Funding Round Breast Cancer Study Leads to New Susceptibility Gene, Potential Treatment Strategies Incyte's Pemazyre Approved in Japan for FGFR1-Positive Rare Blood Cancers Cardiff Oncology Begins Phase II Onvansertib Trial in KRAS-, NRAS-Mutant Colorectal Cancer
